Effects of NUTRIOSE®FB Dietary Fiber Supplementation on Satiety, Body Fat, and Metabolic Syndrome in Overweight Adult Men
This study has been completed.
Sponsor:
Roquette Freres
Collaborator:
Sprim Advanced Life Sciences
Information provided by:
Roquette Freres
ClinicalTrials.gov Identifier:
NCT01044680
First received: January 6, 2010
Last updated: January 7, 2010
Last verified: January 2010
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study was to determine the effects of NUTRIOSE® supplementation on body composition, satiety, and determinants of metabolic syndrome in overweight men.
| Condition | Intervention | Phase |
|---|---|---|
|
Overweight Metabolic Syndrome X |
Dietary Supplement: NUTRIOSE Dietary Supplement: Placebo |
Phase 2 Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Supportive Care |
| Official Title: | The Effects of NUTRIOSE®FB Dietary Fiber Supplementation on the Satiety, Body Fat Distribution, and Metabolic Syndrome Biomarkers of Overweight Adult Chinese Men 20-35 Years of Age. |
Resource links provided by NLM:
Further study details as provided by Roquette Freres:
Primary Outcome Measures:
- Determinants of metabolic syndrome [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
| Enrollment: | 120 |
| Study Start Date: | October 2006 |
| Study Completion Date: | February 2007 |
| Primary Completion Date: | February 2007 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Nutriose
17 g NUTRIOSE consumed twice daily for 12 weeks
|
Dietary Supplement: NUTRIOSE
17 grams of NUTRIOSE consumed twice daily for 12 weeks
|
|
Placebo Comparator: Placebo
17 g maltodextrin consumed twice daily for 12 weeks
|
Dietary Supplement: Placebo
17 g maltodextrin consumed twice daily for 12 weeks
|
Detailed Description:
Previous trials of fiber supplementation have yielded equivocal results on body composition, satiety, and determinants of metabolic syndrome. This double-blind, randomized, placebo-controlled study was conducted to determine the effects of a proprietary soluble dextrin dietary fiber supplement (NUTRIOSE®) on these parameters in overweight males.
Eligibility| Ages Eligible for Study: | 20 Years to 35 Years |
| Genders Eligible for Study: | Male |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria:
- males 20-35 years
- body mass index of 24-28 kg/m2
- current employment and residence at one of three manufacturing plants with a controlled setting and with similar regimented working conditions 7 days a week
Exclusion Criteria:
- current or recent dietary fiber supplementation
- use of lipid-lowering/hypertension medication
- current insulin injection use
- contraindication to fiber supplements, e.g. Crohn's disease
- allergy to wheat products
- recent or current antibiotic use
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01044680
Locations
| China | |
| Tongji University Medical College | |
| Shanghai, China | |
Sponsors and Collaborators
Roquette Freres
Sprim Advanced Life Sciences
Investigators
| Principal Investigator: | Shuguang Li, MD | Tongji University Medical College |
More Information
Publications:
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Laetitia Guerin-Deremaux, Roquette Freres |
| ClinicalTrials.gov Identifier: | NCT01044680 History of Changes |
| Other Study ID Numbers: | 06-10- CN-Roquette-01 |
| Study First Received: | January 6, 2010 |
| Last Updated: | January 7, 2010 |
| Health Authority: | China: Ethics Committee |
Keywords provided by Roquette Freres:
|
fiber metabolic syndrome overweight satiety |
Additional relevant MeSH terms:
|
Overweight Metabolic Syndrome X Body Weight Signs and Symptoms |
Insulin Resistance Hyperinsulinism Glucose Metabolism Disorders Metabolic Diseases |
ClinicalTrials.gov processed this record on June 18, 2013